Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021.

Recent Highlights

• Closed a $13.2 million public offering
• Up listed to the Nasdaq Capital Market
• Hosted a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction
• Received FDA comment to provide clinical sites with ready-to-inject clinical vials of PT00114; to result in IND refiling in the fourth quarter

“During the second quarter and year to date, we made important progress towards advancing PT00114 into the clinic, in order to treat stress-related neuropsychiatric disorders which afflict a growing patient population,” said Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics. “We have a clear clinical path toward major indications. We anticipate rapid efficacy and safety readouts in the first half of 2022.”

Anticipated Upcoming Milestones

• Q4 2021: Re-filing of IND application for PT00114
• Q1 2022: Initiation of Phase I/IIa study for PT00114
• 1H 2022: Initial Data Readout of Phase I/IIa study

Financial Results for the Second Quarter Ended June 30, 2021:

• Net loss attributable to common stockholders for the quarter ended June 30, 2021 was approximately $1.5 million, compared to approximately $0.6 million for the quarter ended June 30, 2020.
• Research and development expense totaled approximately $0.1 million for the quarter ended June 30, 2021, compared to approximately $0.1 million during the quarter ended June 30, 2020.
• General and administrative expense was approximately $1.2 million for the quarter ended June 30, 2021, compared to approximately $0.4 million during the quarter ended June 30, 2020.
• On April 29, 2021, the company closed on an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit. Each unit was comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable at a price of $4.98 per share and will expire five years from issuance. The common stock and warrants comprising the units separated upon closing of the offering and were issued separately.
• As of June 30, 2021, the Company had cash and cash equivalents of approximately $11.9 million.
• As of August 16, 2021, the Company had approximately 16.6 million common shares outstanding.

Select Financial Information

Protagenic Therapeutics, Inc., and SubsidiaryCash, Cash Equivalents, and Current Assets(In U.S. Dollars)(Unaudited)

		June 30,				December 31,
		2021				2020
ASSETS
CURRENT ASSETS
Cash		$	11,932,973			$	671,091
Prepaid expenses			129,167				208,156
TOTAL CURRENT ASSETS			12,062,140				879,247
TOTAL ASSETS		$	12,062,140			$	879,247

Consolidated Statements of Operations (In U.S. Dollars)(Unaudited)

		For the three months endedJune 30,								For the six months ended June 30,
		2021				2020				2021				2020
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development			140,592				52,008				732,943				117,967
General and administrative			1,168,241				436,935				1,782,080				891,712
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES			1,308,833				488,943				2,515,023				1,009,679
LOSS FROM OPERATIONS			(1,308,833	)			(488,943	)			(2,515,023	)			(1,009,679	)
OTHER (EXPENSE) INCOME
Interest income			227				93				232				477
Interest expense			(239,190	)			(54,944	)			(323,127	)			(93,930	)
Change in fair value of derivative liability			-				(23,560	)			83,670				37,189
TOTAL OTHER INCOME (EXPENSES)			(238,963	)			(78,411	)			(239,225	)			(56,264	)
LOSS BEFORE TAX			(1,547,796	)			(567,354	)			(2,754,248	)			(1,065,943	)
INCOME TAX EXPENSE			-				-				-				-
NET LOSS		$	(1,547,796	)		$	(567,354	)		$	(2,754,248	)		$	(1,065,943	)
COMPREHENSIVE LOSS
Other Comprehensive Loss - net of tax
Foreign exchange translation income (loss)			482				1,084				973				(1,335	)
TOTAL COMPREHENSIVE LOSS		$	(1,547,314	)		$	(566,270	)		$	(2,753,275	)		$	(1,067,278	)
Net loss per common share - Basic and Diluted		$	(0.11	)		$	(0.06	)		$	(0.22	)		$	(0.10	)
Weighted average common shares - Basic and Diluted			14,487,277				10,261,419				12,488,906				10,261,419

See accompanying notes to these unaudited consolidated financial statements in our Form 10-Q filed with the SEC August 16, 2021

About Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders. For more information, visit http://www.protagenic.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Protagenic Therapeutics’ product candidates and pre-clinical development and clinical trial plans and activities. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the pre-clinical testing and eventual clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in pre-clinical and clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors described under the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.. Protagenic Therapeutics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Protagenic undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Analyst Contact:Alexander K. Arrow, MD, CFA Chief Financial [e-mail]

Media Contact:James CarbonaraHayden IR(646)[e-mail]